Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Sphingolipid"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Case Report
Article image
Loss-of-Function Variant in the SMPD1 Gene in Progressive Supranuclear Palsy-Richardson Syndrome Patients of Chinese Ancestry
Shen-Yang Lim, Ai Huey Tan, Jia Nee Foo, Yi Jayne Tan, Elaine GY Chew, Azlina Ahmad Annuar, Alfand Marl Dy Closas, Azalea Pajo, Jia Lun Lim, Yi Wen Tay, Anis Nadhirah, Jia Wei Hor, Tzi Shin Toh, Lei Cheng Lit, Jannah Zulkefli, Su Juen Ngim, Weng Khong Lim, Huw R. Morris, Eng-King Tan, Adeline SL Ng
J Mov Disord. 2024;17(2):213-217.   Published online January 31, 2024
DOI: https://doi.org/10.14802/jmd.24009
  • 3,748 View
  • 92 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary Material
Lysosomal dysfunction plays an important role in neurodegenerative diseases, including Parkinson’s disease (PD) and possibly Parkinson-plus syndromes such as progressive supranuclear palsy (PSP). This role is exemplified by the involvement of variants in the GBA1 gene, which results in a deficiency of the lysosomal enzyme glucocerebrosidase and is the most frequently identified genetic factor underlying PD worldwide. Pathogenic variants in the SMPD1 gene are a recessive cause of Niemann–Pick disease types A and B. Here, we provide the first report on an association between a loss-of-function variant in the SMPD1 gene present in a heterozygous state (p.Pro332Arg/p.P332R, which is known to result in reduced lysosomal acid sphingomyelinase activity), with PSP-Richardson syndrome in three unrelated patients of Chinese ancestry.

Citations

Citations to this article as recorded by  
  • The Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy
    Piotr Alster, Natalia Madetko-Alster
    International Journal of Molecular Sciences.2025; 26(9): 3927.     CrossRef
  • Parkinson’s Disease is Predominantly a Genetic Disease
    Shen-Yang Lim, Christine Klein
    Journal of Parkinson’s Disease.2024; 14(3): 467.     CrossRef
  • Identification of Genetic Variants in Progressive Supranuclear Palsy in Southeast Asia
    Adeline Su Lyn Ng, Ai Huey Tan, Yi Jayne Tan, Jia Lun Lim, Michelle Mulan Lian, Alfand Marl Dy Closas, Azlina Ahmad‐Annuar, Shanthi Viswanathan, Yuen Kang Chia, Jia Nee Foo, Weng Khong Lim, Eng‐King Tan, Shen‐Yang Lim
    Movement Disorders.2024; 39(10): 1829.     CrossRef
  • Genetic-based diagnostics of Parkinson’s disease and other Parkinsonian syndromes
    Emma N. Somerville, Ziv Gan-Or
    Expert Review of Molecular Diagnostics.2024; 24(12): 1111.     CrossRef
Review Article
Article image
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Young Eun Huh, Tatiana Usnich, Clemens R. Scherzer, Christine Klein, Sun Ju Chung
J Mov Disord. 2023;16(3):261-278.   Published online June 12, 2023
DOI: https://doi.org/10.14802/jmd.23023
  • 8,342 View
  • 487 Download
  • 12 Web of Science
  • 13 Crossref
AbstractAbstract PDF
Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression and promote the development of a preventive intervention for individuals at a higher risk of a worse disease prognosis. Moreover, the GBA1-regulated pathway provides new perspectives on the pathogenesis of PD, such as dysregulated sphingolipid metabolism, impaired protein quality control, and disrupted endoplasmic reticulum-Golgi trafficking. These perspectives have led to the development of novel disease-modifying therapies for PD targeting the GBA1-regulated pathway by repositioning treatment strategies for Gaucher’s disease. This review summarizes the current hypotheses on a mechanistic link between GBA1 variants and PD and possible therapeutic options for modulating GBA1-regulated pathways in PD patients.

Citations

Citations to this article as recorded by  
  • Male sex accelerates cognitive decline in GBA1 Parkinson’s disease
    Silvia Paola Caminiti, Micol Avenali, Alice Galli, Rachele Malito, Giada Cuconato, Caterina Galandra, Rosaria Calabrese, Andrea Pilotto, Alessandro Padovani, Fabio Blandini, Daniela Perani, Cristina Tassorelli, Enza Maria Valente
    npj Parkinson's Disease.2025;[Epub]     CrossRef
  • Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
    Malco Rossi, Susen Schaake, Tatiana Usnich, Josephine Boehm, Nina Steffen, Nathalie Schell, Clara Krüger, Tuğçe Gül‐Demirkale, Natascha Bahr, Teresa Kleinz, Harutyun Madoev, Björn‐Hergen Laabs, Ziv Gan‐Or, Roy N. Alcalay, Katja Lohmann, Christine Klein
    Movement Disorders.2025; 40(4): 605.     CrossRef
  • Challenges in Gaucher disease: Perspectives from an expert panel
    Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, S. Grace Prakalapakorn, Barry E. Rosenbloom, Dominick A. Tuason, Neal J. Weinreb
    Molecular Genetics and Metabolism.2025; 145(1): 109074.     CrossRef
  • Acetal functionalized iminosugars for targeting β-glucocerebrosidase modulation
    Maria Giulia Davighi, Francesca Clemente, Camilla Matassini, Martina Cacciarini, Damiano Tanini, Andrea Goti, Amelia Morrone, Paolo Paoli, Francesca Cardona
    European Journal of Medicinal Chemistry.2025; 290: 117529.     CrossRef
  • Comparative analysis of methods for measuring glucocerebrosidase enzyme activity in patients with Parkinson’s disease with the GBA1 variant
    Jin Hwangbo, Myung Jun Lee, Sang Jin Kim, Hyun Kyung Park, Jae-heyok Lee
    Frontiers in Neurology.2025;[Epub]     CrossRef
  • A drug screening platform for protein expression levels in neurological disorders
    Farida Emran, Ibrahim Kays, Chiu-An Lo, Yueyang Li, Brian E. Chen
    BioTechniques.2025; : 1.     CrossRef
  • Investigating plasma lipid profiles in association with Parkinson’s disease risk
    Houwen Zhang, Fangzheng Cao, Jialin Yu, Yu Liang, You Wu
    npj Parkinson's Disease.2025;[Epub]     CrossRef
  • Efficient GBA1 editing via HDR with ssODNs by outcompeting pseudogene-mediated gene conversion upon CRISPR/Cas9 cleavage
    Joseph S. Lagas, Monica F. Sentmanat, Xiaoxia Cui
    Frontiers in Genome Editing.2025;[Epub]     CrossRef
  • A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease
    Makaila L. Furderer, Bahafta Berhe, Tiffany C. Chen, Stephen Wincovitch, Xuntian Jiang, Nahid Tayebi, Ellen Sidransky, Tae-Un Han
    International Journal of Molecular Sciences.2024; 25(3): 1827.     CrossRef
  • Towards a Global View of Parkinson's Disease Genetics
    Marzieh Khani, Catalina Cerquera‐Cleves, Mariam Kekenadze, Peter Wild Crea, Andrew B. Singleton, Sara Bandres‐Ciga
    Annals of Neurology.2024; 95(5): 831.     CrossRef
  • Exploring the Association between Cathepsin B and Parkinson’s Disease
    Changhao Lu, Xinyi Cai, Shilin Zhi, Xiaofen Wen, Jiaxin Shen, Tommaso Ercoli, Elena Rita Simula, Carla Masala, Leonardo A. Sechi, Paolo Solla
    Brain Sciences.2024; 14(5): 482.     CrossRef
  • Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
    Xuxiang Zhang, Heng Wu, Beisha Tang, Jifeng Guo
    Translational Neurodegeneration.2024;[Epub]     CrossRef
  • Microglia: roles and genetic risk in Parkinson’s disease
    Alex R. Trainor, Debra S. MacDonald, Jay Penney
    Frontiers in Neuroscience.2024;[Epub]     CrossRef

JMD : Journal of Movement Disorders Twitter
Close layer
TOP